RHY Acquires Genetype Genetic Risk Assessment Business
Filed with ASX · · 4 pages · English
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Pause in Trading
- Market Update - All End of CY24 Milestones Attained
- Strong Demand in Share Placement to Raise $3.5 million
- Receipt of Research & Development Tax Incentive
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
Later from Rhythm Biosciences
- Completion of Genetype Risk Assessment Portfolio Acquisition
- About the Genetype Acquisition
- Quarterly Activities Report and Appendix 4C - Dec24
- Genetype Commercial Integration Completion
- RHY Investor Webinar
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences